How can Europe remain at the forefront of innovation to the benefit of patients with rare diseases?


Wednesday 8 July 2020, 11.00-12.00 CET

Organized by:




·       Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

·       Olga Solomon, Head of Medicines: Policy, Authorisation and Monitoring, Unit DG SANTE, European Commission

·       Jack Scannell, Founder, JW Scannell Analytics Ltd.

·       Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)

·       Duane Schulthess, Managing Director, Vital Transformation, (moderator)

The COVID-19 pandemic acts as a magnifying glass for existing challenges related to rare diseases, in research, clinical trial continuation as well as in availability of treatments and care. Yet, there are lessons to be learned from this crisis: from the potential of stronger cooperation to foster development and access to therapies, to the opportunities brought about by digital health and telemedicine solutions.

Building on an Office of Health Economics analysis on the economic and financial challenges of developing therapies for rare diseases, recently unveiled at the 10th European Conference on Rare Diseases (ECRD), EUCOPE is organising a webinar to discuss future outlooks on rare diseases innovation to the benefit of patients in Europe. Using the report as a starting point, we will analyse new and existing trends impacting the rare disease community with the support of a multi-stakeholder panel of speakers including policy makers, patients, investors and small- to mid-sized pharmaceutical industry.

Related information

Copyright © 2002 - 2020 Enerca

Co-funded by the Health Programme of the European Union.